Výsledky vyhledávání - "Clay T Cramer"

Akademický článek

Absence of effect of steady state bempedoic acid on cardiac repolarization: Results of a thorough QT/QTc study in healthy volunteers

Autor: Benny M. Amore, Clay T. Cramer, Diane E. MacDougall, William J. Sasiela, Maurice G. Emery

Publikováno v: Clinical and Translational Science, Vol 14, Iss 6, Pp 2487-2496 (2021)

Abstract Bempedoic acid is an inhibitor of adenosine triphosphate–citrate lyase approved for use in adults with hypercholesterolemia. Nonclinical studies assessed binding to the human ether‐a‐go‐go–related gene (hERG) potassium channel in v

Externí odkaz: https://doaj.org/article/d673bee841e24a1c9ed715ea6899fac6

Zobrazit plný text záznamu

Akademický článek

ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK

Autor: Sergey Filippov, Stephen L. Pinkosky, Richard J. Lister, Catherine Pawloski, Jeffrey C. Hanselman, Clay T. Cramer, Rai Ajit K. Srivastava, Timothy R. Hurley, Cheryl D. Bradshaw, Mark A. Spahr, Roger S. Newton

Publikováno v: Journal of Lipid Research, Vol 54, Iss 8, Pp 2095-2108 (2013)

ETC-1002 is an investigational drug currently in Phase 2 development for treatment of dyslipidemia and other cardiometabolic risk factors. In dyslipidemic subjects, ETC-1002 not only reduces plasma LDL cholesterol but also significantly attenuates le

Externí odkaz: https://doaj.org/article/5dade5c025dd481597a6c9e3ada9030c

Zobrazit plný text záznamu

Akademický článek

AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism[S]

Autor: Stephen L. Pinkosky, Sergey Filippov, Rai Ajit K. Srivastava, Jeffrey C. Hanselman, Cheryl D. Bradshaw, Timothy R. Hurley, Clay T. Cramer, Mark A. Spahr, Ashley F. Brant, Jacob L. Houghton, Chris Baker, Mark Naples, Khosrow Adeli, Roger S. Newton

Publikováno v: Journal of Lipid Research, Vol 54, Iss 1, Pp 134-151 (2013)

ETC-1002 (8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid) is a novel investigational drug being developed for the treatment of dyslipidemia and other cardio-metabolic risk factors. The hypolipidemic, anti-atherosclerotic, anti-obesity, and gluc

Externí odkaz: https://doaj.org/article/cec4f54dcb2f41e99d4df80fe4b930fe

Zobrazit plný text záznamu

Akademický článek

AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases

Autor: Rai Ajit K. Srivastava, Stephen L. Pinkosky, Sergey Filippov, Jeffrey C. Hanselman, Clay T. Cramer, Roger S. Newton

Publikováno v: Journal of Lipid Research, Vol 53, Iss 12, Pp 2490-2514 (2012)

The adenosine monophosphate-activated protein kinase (AMPK) is a metabolic sensor of energy metabolism at the cellular as well as whole-body level. It is activated by low energy status that triggers a switch from ATP-consuming anabolic pathways to AT

Externí odkaz: https://doaj.org/article/bccb674450944c288fdc9d672cd04466

Zobrazit plný text záznamu

Akademický článek

Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome

Autor: Clay T. Cramer, Brian Goetz, Krista L.M. Hopson, Gregory J. Fici, Rose M. Ackermann, Stephen C. Brown, Charles L. Bisgaier, W.G. Rajeswaran, Daniela C. Oniciu, Michael E. Pape

Publikováno v: Journal of Lipid Research, Vol 45, Iss 7, Pp 1289-1301 (2004)

We have identified a novel ω-hydroxy-alkanedicarboxylic acid, ESP 55016, that favorably alters serum lipid variables in obese female Zucker (fa/fa) rats. ESP 55016 reduced serum non-HDL-cholesterol (non-HDL-C), triglyceride, and nonesterified fatty

Externí odkaz: https://doaj.org/article/6e66dc604caa440cad0b2da77bb5ad67

Zobrazit plný text záznamu

Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial

Autor: Clay T. Cramer, Narendra D. Lalwani, Jeffrey C. Hanselman, Lulu Ren Sterling, Diane E. MacDougall

Publikováno v: Journal of Clinical Lipidology. 13:568-579

Background Bempedoic acid is an oral, once-daily, first-in-class medication being developed to treat hypercholesterolemia. Objective The aim of the study was to assess the low-density lipoprotein cholesterol (LDL-C)–lowering efficacy of bempedoic a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::321735c9992ecab2b2fbd59820d1f697
https://doi.org/10.1016/j.jacl.2019.05.003

Zobrazit plný text záznamu

Measurement of bempedoic acid and its keto metabolite in human plasma and urine using solid phase extraction and electrospray LC-MS/MS

Autor: Ronald Shoup, Cameron Brown, Clay T. Cramer, Brian J. Engel, Karen Preusch

Publikováno v: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 1154

Bempedoic acid, a new therapeutic for treatment of hypercholesterolemia, inhibits hepatic ATP-citrate lyase in the cholesterol synthesis pathway after its conjugation with coenzyme A. Sensitive and selective methods were required to study the pharmac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e2db3a3451e5113fbbf97eb68921ab4
https://pubmed.ncbi.nlm.nih.gov/32763847

Zobrazit plný text záznamu